Blinding for clinical trials. Does it matter?;El «ciego» en los ensayos clínicos ¿importa?

Revista Medica de Chile

Volumn 132, Issue 9, 2004, Pages 1137-1139

  Letelier S, Luz María ^a,b   Manríquez M, Juan Jorge ^a   Claro GA, Juan Carlos ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL DR SÓTERO DEL RÍO   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EVALUATION; MEDICAL RESEARCH; METHODOLOGY; RANDOMIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HUMAN; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SINGLE BLIND PROCEDURE;

DOUBLE-BLIND METHOD; HUMANS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SINGLE-BLIND METHOD;

EID: 12444268320     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. PANTOJA T, LETELIER LM, NEUMANN I. El análisis crítico de la información publicada en la literatura médica. Rev Méd Chile 2004; 132: 513-5.
2. GUYATT GH, RENNIE D. Users' Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press, 2002.
3. DAY S, ALTMAN D. Statistics notes: blinding in clinical trials and other studies. BMJ 2000; 321: 504.
4. DEVEREAUX PJ, MANNS BJ, GHALI WA QUAN H, LACHETTI C, MONTORI V ET AL. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001; 285: 2000-3.
5. SCHULZ K, CHALMERS I, ALTMAN D. The landscape and lexicon of blinding in randomized trials. Ann Intern Med 2002; 136: 254-9.
6. SCHULZ K, GRIMES D. Blinding in randomized trials: hiding who got what. Lancet 2002; 359: 696-700.
7. SCHULZ K, CHALMERS I, HAYES R, ALTMAN DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
8. BANG H, NI L, DAVIS C. Assessment of blinding in clinical trials. Control Clin Trials 2004; 25: 143-56.